On Jan. 19, Dong-A ST NeuroBo Pharmaceuticals announced the commencement of the global Phase 2 Part 2 clinical trial for its Metabolic dysfunction-associated steatohepatitis (MASH) treatment DA-1241.Last May, the company received approval from the U.S. Food and Drug Administration (FDA) for the glob
Daewoong Pharmaceutical is rapidly securing its position in the market by consecutively acquiring patents related to the treatment of autoimmune diseases. The company announced on Oct. 4 that it has registered three patents related to autoimmune disease treatments over the past six months.To date, D
SK biopharm’s U.S. R&D subsidiary, Proteovant Therapeutics, announced on Sept. 27 that it will present its latest research findings in the Targeted Protein Degradation (TPD) field at the “Discovery on Target 2023” held in Boston, Massachusetts, from Sept. 27 to 28, local time.In this presentation, P
JW Pharmaceutical announced on July 20 that it has obtained a patent for the Wnt target hair loss treatment JW0061 from the Australian Patent Office.This patent is related to a new drug candidate for hair loss treatment based on the Wnt signaling pathway and aims to protect “a new heterocyclic induc
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Daewoong logged 1Q23 OP of W31bn, slightly beating consensus. R&D and other SG&A expenses, which have been the main cause of margin erosion, are starting to improve and should normalize towards 2H23.
Daewoong Pharmaceutical announced that it signed an agreement to license its autoimmune disease drug candidate DWP213388 to Vitalli Bio, a subsidiary of Aditum Bio, a U.S. biotech investment company, at the Korea-U.S. Digital and Bio-health Business Forum held in Boston, the United States, on April
GC Biopharma announced on Feb. 28 that it has signed an asset purchase agreement with Catalyst Biosciences, a US drug developer, for a pipeline for a coagulation disease.Through this contract, GC Biopharma will acquire a total of three pipelines, including Marzeptacog alfa (MarzAA) under development
ST Pharm, a subsidiary of Dong-A Socio Group, announced on Feb. 23 that it signed an agreement with Multiverse Pharma in the United States for joint research on new antibody-encoding (AER) platform technology and biobetter mRNA drugs.Under the agreement, ST Pharm and Multiverse Pharma will develop f
Daewoong Pharmaceutical will launch a phase 1 clinical trial of a new drug for autoimmune diseases in the United States. It is a first-in-class medication in the autoimmune disease family that simultaneously inhibits two enzymes involved in immune cell activation. The clinical trial on 72 patients i
JW Pharmaceutical announced on Oct. 31 that it will make a poster presentation on the results of a preclinical study on JW0061, a Wnt target hair loss treatment, at Wnt 2022, a conference to be held in Japan for five days from Nov. 15.Wnt is an acronym in the field of genetics that stands for 'W
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. We raise our 2Q22 sales and OP estimates (parent basis) for Daewoong Pharm to W299.5bn and W29.2bn, respectively, as we hike our Nabota sales forecast to W131.4bn. We draw attention to the planned la
Standigm Inc., a Korean leading workflow artificial intelligence (AI) drug discovery company, announced on Nov. 3 that the company has filed PCT (Patent Cooperation Treaty) patent application covering AI-driven repurposed drugs for primary mitochondrial disease.The company collaborated with a U.S. h
Hanmi Pharmaceutical has risen to the top in the Korean orphan drug industry. The company has a total of 17 drugs that have been designated as orphan drugs in the United States, Europe and Korea.The company invests about 20 percent of its sales revenue, earned through the sales of drugs developed in
Chong Kun Dang announced on Aug. 26 that the U.S. Food and Drug Administration (FDA) has approved Cara Therapeutics and Vifor Pharma’s Korsuva, a treatment for uremic pruritus. The company is the sole distributor of the drug in Korea.In 2012, Chong Kun Dang signed a contract with Cara Therapeutics,
Hanmi Pharmaceutical announced on Sept. 25 that it presented the results of three studies on potential first-in-class nonalcoholic steatohepatitis (NASH) treatment LAPSTriple Agonist (HM15211) and two studies on first-in-class obesity treatment LAPSglucagon Analog (HM15136) in the 56th meeting of th
Daewoong Pharmaceutical has established iN Therapeutics, a new company specializing in new drug development. The move is intended to secure R&D flexibility and speed up commercialization of its new drug pipelines.The company spun out its ion channel new drug development platform and promising pipeli
The authors are analysts of NH Investment & Securities. They can be reached at william.ku@nhqv.com and weihan@nhqv.com, respectively. – Ed. 1. Confident towards domestic bio sector’s mid/long-term growth potentialDomestic bio sector: 20-year-long new drug development historyKorea’s first domesticall
The authors are analysts of NH Investment & Securities. They can be reached at william.ku@nhqv.com and weihan@nhqv.com, respectively. – Ed. 1. Pay attention to newly-listed players displaying rapid progress in Covid-19 vaccine developmentNewly-listed biotech firms faring well amid pandemicThis year,
JW Pharmaceutical announced on May 12 that the results of phase 1a clinical trials (single dose) on CWP291, a candidate material for acute myeloid leukemia (AML), has been published in the online edition of Blood Advances, a journal published by the American Society of Hematology (ASH).CWP291 is a t
Daewoong Pharmaceutical will unveil its overseas expansion strategy and a roadmap for the development of new drugs at the JP Morgan Healthcare Conference in San Francisco on Jan. 15 (local time), the company announced on Jan. 9.The JP Morgan Healthcare Conference is the world's most prestigious